News
Novavax said Monday that the Food and Drug Administration was asking the company to run a new clinical trial of its vaccine.
“Under Secretary Kennedy’s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to ...
Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...
5don MSN
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...
Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...
Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...
Novavax Inc. shares fell after the Wall Street Journal reported that US regulators asked the company to conduct another ...
The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...
Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...
3d
Health and Me on MSNRight Before Approval, FDA Again Scrutinizes Novavax Covid-19 VaccineNovavax is working with the FDA to meet additional requirements and hopes to secure full approval as soon as possible.
Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results